» Articles » PMID: 33571915

Autonomic Dysregulation As an Early Pathologic Feature of Huntington Disease

Overview
Journal Auton Neurosci
Publisher Elsevier
Specialty Neurology
Date 2021 Feb 11
PMID 33571915
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Autonomic nervous system (ANS) dysfunction has been described in adults with motor-manifest Huntington's Disease (HD) or those who are near their predicted motor onset. It is unclear if ANS dysfunction is present years prior to the onset of motor symptoms of HD. To bridge this gap in knowledge, we compared crude markers of ANS function between children with the gene-expansion that causes HD (GE group) who were decades from their predicted motor onset and gene-non-expanded children (GNE group).

Methods: We included participants from the Kids-HD study who were <18 years old. Linear mixed effects regression models were constructed that controlled for sex, age, and BMI, and included a random effect per participant and per family. We compared resting heart rate (rHR), core body temperature (CBT), systolic blood pressure (SBP), and diastolic blood pressure (DBP) between the GE (n = 84) and GNE (n = 238) groups. We then grouped participants from the GE group based on their predicted years to onset (YTO) and compared their vital signs to the GNE group.

Results: The GE group had higher rHR (∆ = 3.83, p = 0.0064), SBP (∆ = 2.38, p = 0.032), and CBT (∆ = 0.16, t = 2.92, p = 0.007). The mean rHR and CBT became significantly elevated compared to the GNE group in participants who had 15-25 YTO and those who had <15 YTO. The mean SBP of participants who had 25-35 YTO was significantly elevated compared to the GNE group.

Conclusion: ANS dysfunction in HD seems to occur approximately 20 years prior to the predicted onset of motor symptoms of HD.

Citing Articles

β-Blocker Use and Delayed Onset and Progression of Huntington Disease.

Schultz J, Ogilvie A, Harshman L, Nopoulos P JAMA Neurol. 2024; 82(1):85-92.

PMID: 39621338 PMC: 11612910. DOI: 10.1001/jamaneurol.2024.4108.


Investigating the Interplay between Cardiovascular and Neurodegenerative Disease.

Cousineau J, Dawe A, Alpaugh M Biology (Basel). 2024; 13(10).

PMID: 39452073 PMC: 11505144. DOI: 10.3390/biology13100764.


Mutant Huntingtin Drives Development of an Advantageous Brain Early in Life: Evidence in Support of Antagonistic Pleiotropy.

Neema M, Schultz J, Langbehn D, Conrad A, Epping E, Magnotta V Ann Neurol. 2024; 96(5):1006-1019.

PMID: 39115048 PMC: 11496017. DOI: 10.1002/ana.27046.


The phase coherence of the neurovascular unit is reduced in Huntington's disease.

Bjerkan J, Kobal J, Lancaster G, Sesok S, Meglic B, McClintock P Brain Commun. 2024; 6(3):fcae166.

PMID: 38938620 PMC: 11210076. DOI: 10.1093/braincomms/fcae166.


Modulation of the Circadian Rhythm and Oxidative Stress as Molecular Targets to Improve Vascular Dementia: A Pharmacological Perspective.

Trujillo-Rangel W, Acuna-Vaca S, Padilla-Ponce D, Garcia-Mercado F, Torres-Mendoza B, Pacheco-Moises F Int J Mol Sci. 2024; 25(8).

PMID: 38673986 PMC: 11050388. DOI: 10.3390/ijms25084401.


References
1.
Kannel W . Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000; 13(1 Pt 2):3S-10S. DOI: 10.1016/s0895-7061(99)00252-6. View

2.
Langbehn D, Brinkman R, Falush D, Paulsen J, Hayden M . A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65(4):267-77. DOI: 10.1111/j.1399-0004.2004.00241.x. View

3.
Scahill R, Zeun P, Osborne-Crowley K, Johnson E, Gregory S, Parker C . Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 2020; 19(6):502-512. PMC: 7254065. DOI: 10.1016/S1474-4422(20)30143-5. View

4.
Tabrizi S, Scahill R, Owen G, Durr A, Leavitt B, Roos R . Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013; 12(7):637-49. DOI: 10.1016/S1474-4422(13)70088-7. View

5.
Paulsen J, Long J, Ross C, Harrington D, Erwin C, Williams J . Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014; 13(12):1193-201. PMC: 4373455. DOI: 10.1016/S1474-4422(14)70238-8. View